FTO and obesity disorder: Their study presented 7d as the first FTO inhibitor with anticonvulsant activity, as affirmed from an animal model of pharmaco-resistant epilepsy (termed six Hz model) [114]; yet future investigations on this inhibitor effect on FTO activity in relation to obesity and cancers as FTO-associated disorders would be interesting.